What is the 13F Pro Quality Score for SNOA?

13F Pro ranks Sonoma Pharmaceuticals, Inc. (SNOA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SNOA's current score at https://13fpro.ai/research/SNOA (free sign-up required for the full ranking).

Where does 13F Pro source SNOA data?

All Sonoma Pharmaceuticals, Inc. fundamentals and ownership data come directly from SEC EDGAR. Sonoma Pharmaceuticals, Inc. files with the SEC under CIK 1367083. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SNOA in?

Sonoma Pharmaceuticals, Inc. (SNOA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is SNOA research updated on 13F Pro?

SNOA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Sonoma Pharmaceuticals, Inc.(SNOA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1367083 SNOA stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $19.5M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

SNOA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Sonoma Pharmaceuticals, Inc. (SNOA), a Healthcare sector company. SNOA is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $19.5m in revenue. Based on the latest XBRL financial filings (Q4 2026), Sonoma Pharmaceuticals, Inc. reports quarterly revenue of $5.6M, net income of $-581.0K, free cash flow of $-548.0K. Top institutional holders of SNOA by reported 13-F value include GEODE CAPITAL MANAGEMENT,, VANGUARD CAPITAL MANAGEMENT, DRW Securities,, based on the most recent SEC filings. SNOA trades on the Nasdaq exchange and files with the SEC under CIK 1367083. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SNOA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Sonoma Pharmaceuticals, Inc. directly from SEC EDGAR.

Revenue

Q4 2026

$5.6M

Net Income

Q4 2026

$-581.0K

Free Cash Flow

Q4 2026

$-548.0K

D/E Ratio

Q4 2026

0.07

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+36.7% YoY

$19.5MFY 2026

FY23 $13.3MFY24 $12.7MFY25 $14.3MFY26 $19.5M

Net Income

+8.2% YoY

$-3.2MFY 2026

FY23 $-5.2MFY24 $-4.8MFY25 $-3.5MFY26 $-3.2M

Operating Income

+33.7% YoY

$-2.5MFY 2026

FY23 $-4.6MFY24 $-4.7MFY25 $-3.7MFY26 $-2.5M

EPS (Diluted)

+32.3% YoY

$-1.89FY 2026

FY23 $-1.52FY24 $-10.63FY25 $-2.79FY26 $-1.89

Total Assets

+1.9% YoY

$14.0MFY 2026

FY23 $16.2MFY24 $14.7MFY25 $13.7MFY26 $14.0M

Total Debt

+0.9% YoY

$222.0KFY 2026

FY23 $431.0KFY24 $323.0KFY25 $220.0KFY26 $222.0K

Op. Cash Flow

-4369.3% YoY

$-3.9MFY 2026

FY23 $-6.2MFY24 $-2.4MFY25 $-88.0KFY26 $-3.9M

Metric	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	$19.5M +36.7%	$14.3M +12.2%	$12.7M -4.0%	$13.3M +5.1%	$12.6M -32.2%	$18.6M
Net Income	$-3.2M +8.2%	$-3.5M +28.5%	$-4.8M +6.1%	$-5.2M -1.3%	$-5.1M -28.8%	$-4.0M
Operating Income	$-2.5M +33.7%	$-3.7M +21.1%	$-4.7M -2.9%	$-4.6M +22.4%	$-5.9M -70.7%	$-3.4M
EPS (Diluted)	$-1.89 +32.3%	$-2.79 +73.8%	$-10.63 -599.3%	$-1.52 +20.8%	$-1.92	—
Total Assets	$14.0M +1.9%	$13.7M -7.1%	$14.7M -9.2%	$16.2M -13.9%	$18.8M +25.7%	$15.0M
Total Debt	$222.0K +0.9%	$220.0K -31.9%	$323.0K -25.1%	$431.0K	$0.00 -100.0%	$1.9M
Operating Cash Flow	$-3.9M -4369.3%	$-88.0K +96.3%	$-2.4M +61.0%	$-6.2M -44.8%	$-4.2M -25.8%	$-3.4M

AI Insight: SNOA Financial Trends

Sonoma remains unprofitable with volatile quarterly revenue between $4M–$6M and persistent operating losses, though debt-free balance sheet provides runway.

• Revenue fluctuated $4M–$6M over eight quarters; Q3 2025 and Q1 2026 both reached $6M, suggesting potential demand pockets.

• Operating income improved to near-breakeven ($0M) in Q3 2025 and Q1 2026, vs. $-1M in prior quarters.

• Equity declined from $5M (Q2–Q3 2024) to $3M (Q4 2025–Q1 2026), reflecting cumulative losses eroding capital.

⚠ Operating cash flow remains negative in most quarters (Q2 2025: $-2M); company is burning cash despite zero debt.

⚠ Equity down 40% from $5M to $3M since Q2 2024; limited runway if losses continue and no external capital raised.

AI Insight: SNOA Ratio Trends

Operating margin improved sharply to -6.3% in Q1 2026, best quarter in dataset, but profitability remains deeply negative across all metrics.

• Operating margin recovered from -15.6% in Q4 2025 to -6.3% in Q1 2026, continuing uptrend from -27.3% in Q2 2025.

• Net profit margin improved to -10.4% in Q1 2026 from -18.8% in Q4 2025, narrowest loss in trailing data.

• ROIC deteriorated to -42.3% in Q1 2026 from -35.1% in Q3 2025, reversing prior quarter's modest improvement.

⚠ Company remains unprofitable across all core metrics; TTM operating margin -12.6% despite Q1 2026 operational gains.

⚠ ROE collapsed to -75.1% in Q1 2026 from -56.4% in Q3 2025; shareholder value destruction persists.

⚠ Leverage stable (D/E 0.00–0.07 range) but irrelevant given sustained negative returns on deployed capital.

Get alerted when SNOA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Sonoma Pharmaceuticals, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SNOA

GEODE CAPITAL MANAGEMENT, LLC
$42.5K19,941 sh
VANGUARD CAPITAL MANAGEMENT LLC
$40.0K18,787 sh
DRW Securities, LLC
$25.6K12,015 sh
McKinley Carter Wealth Services, Inc.
$23.8K11,193 sh
MORGAN STANLEY
$4.3K2,004 sh
CITIGROUP INC
$3.0K1,425 sh
Tower Research Capital LLC (TRC)
$2.6K1,231 sh
OSAIC HOLDINGS, INC.
$1.1K500 sh
BlackRock, Inc.
$241.00113 sh
VANGUARD FIDUCIARY TRUST CO
$213.00100 sh

Fund	Value	Shares
GEODE CAPITAL MANAGEMENT, LLC	$42.5K	19,941
VANGUARD CAPITAL MANAGEMENT LLC	$40.0K	18,787
DRW Securities, LLC	$25.6K	12,015
McKinley Carter Wealth Services, Inc.	$23.8K	11,193
MORGAN STANLEY	$4.3K	2,004
CITIGROUP INC	$3.0K	1,425
Tower Research Capital LLC (TRC)	$2.6K	1,231
OSAIC HOLDINGS, INC.	$1.1K	500
BlackRock, Inc.	$241.00	113
VANGUARD FIDUCIARY TRUST CO	$213.00	100

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SNOA on your watchlist

Track score changes the day Sonoma Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SNOA a good stock to buy?

13F Pro's AI-powered analysis of Sonoma Pharmaceuticals, Inc. (SNOA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SNOA are available on the SNOA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own SNOA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SNOA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Sonoma Pharmaceuticals, Inc.'s investment landscape.